PropertyValue
?:abstract
  • As of July 9, 2020, there were over 12 million confirmed cases of COVID-19 across the globe, with > 550,000 deaths Many European countries including Belgium, the United Kingdom, Italy, and Spain have had the highest numbers of fatalities per capita 1 This demonstrates the potential for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus to overwhelm even the most advanced healthcare systems despite extreme societal interventions Since its emergence, SARS-CoV-2 has disseminated across the globe, impacting the structure of global societies, infrastructure and economies Patients with alopecia are a diverse group who, for various indications, are prescribed a number of anti-microbials and anti-androgen treatments in addition to immunomodulatory therapies such as hydroxychloroquine, oral corticosteroids and a range of broad immunosuppressants These drugs are being scrutinized for their capacity to potentially impact SARS-CoV-2 outcomes We examine these treatments and highlight the critical role that patient registries will play in generating real-world evidence to assess their impact on COVID-19 outcomes
is ?:annotates of
?:creator
?:journal
  • Clinics_in_Dermatology
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Shedding light on therapeutics in alopecia and their relevance to COVID-19
?:type
?:who_covidence_id
  • #978246
?:year
  • 2020

Metadata

Anon_0  
expand all